Home›Trial›NCT05117840
NCT05117840ACTIVE NOT RECRUITING

Screening for High Frequency Malignant Disease

Study Summary

The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.

Conditions
Lung Cancer
Interventions / Drugs
Low-dose CT scan
View on ClinicalTrials.gov ↗
Sponsor
GH
Guardant Health
Oncology Diagnostics
D41/100
Study Details
Enrollment12000 participants
Primary Completion—
Lead SponsorGuardant Health, Inc.
Data Retrieved2026-04-11 04:14:36.379915+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 12,000 participants
Sponsor Catalyst Profile

Guardant Health (GH) is the sponsoring company for this trial. BiotechSign currently grades this company D (41/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

GH Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.